Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 135

1.

High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome.

Fili M, Lundell G, Lundell M, Seregard S.

Br J Ophthalmol. 2014 Oct;98(10):1349-54. doi: 10.1136/bjophthalmol-2014-305055. Epub 2014 May 13.

PMID:
24825846
2.

The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma.

American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address: paulfinger@eyecancer.com; ABS – OOTF Committee.

Brachytherapy. 2014 Jan-Feb;13(1):1-14. doi: 10.1016/j.brachy.2013.11.008. Epub 2013 Dec 24.

3.

Development and evaluation of a nanoparticle-based immunoassay for determining paclitaxel concentrations on routine clinical analyzers.

Cline DJ, Zhang H, Lundell GD, Harney RL, Riaz HK, Jarrah J, Li Y, Miyazaki M, Courtney JB, Baburina I, Salamone SJ.

Ther Drug Monit. 2013 Dec;35(6):809-15. doi: 10.1097/FTD.0b013e318296be01.

PMID:
24263640
4.

An automated nanoparticle-based homogeneous immunoassay for determining docetaxel concentrations in plasma.

Cline DJ, Zhang H, Lundell GD, Harney RL, Riaz HK, Jarrah J, Li Y, Miyazaki M, Courtney JB, Baburina I, Salamone SJ.

Ther Drug Monit. 2013 Dec;35(6):803-8. doi: 10.1097/FTD.0b013e31829617ea.

PMID:
24263639
5.

Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine.

Abraham-Nordling M, Wallin G, Träisk F, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Asman P, Lundell G, Törring O; Thyroid Study Group of TT 96.

Eur J Endocrinol. 2010 Oct;163(4):651-7. doi: 10.1530/EJE-10-0475. Epub 2010 Jul 21.

6.

Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.

Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, Lundell GD, McMillin G, Milano G, Salamone SJ.

Ther Drug Monit. 2009 Dec;31(6):688-94. doi: 10.1519/JSC.0b013e3181b866d0.

PMID:
19935361
7.

Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.

Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törring O, Wallin G, Asman P, Lundell G; Thyroid Study Group of TT 96.

J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7. doi: 10.1210/jc.2009-0747. Epub 2009 Sep 1.

PMID:
19723755
8.

Determination of busulfan in human plasma using an ELISA format.

Courtney JB, Harney R, Li Y, Lundell G, McMillin GA, Agarwal G, Juenke JM, Mathew A, Gonzalez-Espinoza R, Fleisher M, Salamone SJ.

Ther Drug Monit. 2009 Aug;31(4):489-94. doi: 10.1097/FTD.0b013e3181a8c99c.

PMID:
19494794
9.

Motesanib diphosphate in progressive differentiated thyroid cancer.

Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group.

N Engl J Med. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853.

10.

Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005.

Abraham-Nordling M, Törring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jörneskog G, Wallin G.

Eur J Endocrinol. 2008 Jun;158(6):823-7. doi: 10.1530/EJE-07-0877.

11.

TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.

Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O.

Eur J Endocrinol. 2008 Jan;158(1):69-75. doi: 10.1530/EJE-07-0450.

12.

Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program.

Hansson J, Bergenmar M, Hofer PA, Lundell G, Månsson-Brahme E, Ringborg U, Synnerstad I, Bratel AT, Wennberg AM, Rosdahl I.

J Clin Oncol. 2007 Jul 1;25(19):2819-24.

PMID:
17602087
13.

Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease.

Abraham-Nordling M, Wallin G, Lundell G, Törring O.

Eur J Endocrinol. 2007 Feb;156(2):173-9.

14.

Predictors of outcome in patients with papillary thyroid carcinoma.

Kjellman P, Zedenius J, Lundell G, Bäckdahl M, Farnebo LO, Hamberger B, Larsson C, Wallin G.

Eur J Surg Oncol. 2006 Apr;32(3):345-52. Epub 2006 Feb 3.

PMID:
16459050
15.

Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.

Abraham-Nordling M, Törring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G.

Thyroid. 2005 Nov;15(11):1279-86.

PMID:
16356093
16.

Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma.

Wersäll PJ, Blomgren H, Lax I, Kälkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Näslund I, Pisa P, Svedman C.

Radiother Oncol. 2005 Oct;77(1):88-95. Epub 2005 Jun 20.

PMID:
15972239
17.

Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.

Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S.

Ophthalmology. 2005 May;112(5):834-40.

PMID:
15878063
18.

Anaplastic giant cell thyroid carcinoma.

Wallin G, Lundell G, Tennvall J.

Scand J Surg. 2004;93(4):272-7. Review.

PMID:
15658667
19.

Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer.

Tell R, Lundell G, Nilsson B, Sjödin H, Lewin F, Lewensohn R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):395-400.

PMID:
15380571
20.

Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis.

Seregard S, Lundell G, Svedberg H, Kivelä T.

Ophthalmology. 2004 Jun;111(6):1228-32.

PMID:
15177976

Supplemental Content

Loading ...
Support Center